MK-677 vs. Sermorelin: What the Evidence and Safety Data Actually Show

MK-677 is frequently marketed alongside sermorelin as if the two were interchangeable, both "growth hormone peptides" with the same tradeoffs. That framing is wrong on its first word: MK-677 isn't a peptide at all. It's an orally active, non-peptide small molecule — ibutamoren mesylate — and its own clinical trial record includes a real, controlled safety signal that sermorelin's never has.

Not a peptide, and taken differently

Sermorelin is injected — a 29-amino-acid peptide fragment of growth-hormone-releasing hormone, requiring reconstitution and a subcutaneous injection. MK-677 is a pill. It's an oral ghrelin-receptor (GHS-R1a) agonist, the same receptor class ipamorelin targets, but a chemically distinct small molecule rather than a peptide chain — which is exactly why it's stable enough to survive oral dosing where a peptide typically wouldn't. That also means this site's reconstitution calculator suite — built for converting a vial and diluent into a syringe volume — has no MK-677 route, and shouldn't: there's no vial to reconstitute. If a page tells you to calculate an MK-677 "dose" in mL, it's describing a different product than what MK-677 actually is.

Regulatory status: a lower floor than sermorelin's, not the same one

Sermorelin, discussed in our fuller GH-axis comparisons, at least had a real FDA-approved product once — Geref, discontinued today but genuinely reviewed and marketed for pediatric growth-hormone deficiency from 1990 onward. MK-677 has never had anything comparable. A direct DailyMed search for "ibutamoren" returns two results, and reading the underlying structured data on the more recent one shows exactly what they are: a bulk ingredient for animal drug compounding, filed by a repackager — not a human drug product, not an FDA review of safety or efficacy for use in people at all¹. That's a meaningfully lower regulatory floor than "no approval yet" — the only FDA-adjacent paperwork on file for this compound doesn't concern human use.

FDA's own 503A bulk drug substances list — the same document that confirms sermorelin, ipamorelin, and CJC-1295 sit outside its three nomination categories — places Ibutamoren Mesylate directly under "Category 2: Bulk Drug Substances that Raise Significant Safety Risks," alongside cesium chloride and domperidone². That's not a neutral or pending status; it's FDA's own flagged-safety-concern category, and it's a genuinely different regulatory posture than any of sermorelin, ipamorelin, or CJC-1295 occupy.

The trial evidence: real, controlled, and it surfaced real problems

Here's where this comparison gets more nuanced than "MK-677 is riskier, full stop." MK-677 actually has better-controlled adult trial data than sermorelin does — sermorelin's adult evidence is a single small, uncontrolled, combination-therapy chart review³. MK-677's key trial is a real 2-year, double-blind, randomized, placebo-controlled study: 65 healthy adults aged 60 to 81, taking 25 mg of oral MK-677 or placebo daily⁴. That's a genuinely better study design than anything sermorelin has behind it in adults — and it's exactly what surfaced the concerns below.

Over 12 months, MK-677 significantly increased fat-free mass relative to placebo (change of +1.1 kg vs. −0.5 kg, P<0.001) and produced real, measurable growth-hormone and IGF-1 increases into the young-adult range. It also, in the trial's own words: raised fasting blood glucose by an average of 5 mg/dL (P=0.015) with a decrease in insulin sensitivity; raised cortisol levels by 47 nmol/L (P=0.020); and produced the most frequent side effects as "an increase in appetite that subsided in a few months and transient, mild lower-extremity edema and muscle pain." Despite the fat-free mass gain, the trial found no resulting improvement in strength or function — the added lean tissue didn't translate into measured performance⁴. The trial's own editorial companion, published in the same journal issue by a separate author, is titled plainly: "Use of growth hormone secretagogues to prevent or treat the effects of aging: not yet ready for prime time⁵." A broader 2018 review of the drug class corroborates the specific concern independently: available studies show GH secretagogues "are well tolerated, with some concern for increases in blood glucose because of decreases in insulin sensitivity⁶."

A trial that was stopped early — for a cardiac safety signal

The more serious finding sits in a different, smaller trial. A 2010 multicenter, randomized, double-blind, placebo-controlled Phase 2b study tested MK-677 (25 mg/day) in 123 elderly patients recovering from hip fracture, measuring functional recovery and IGF-1 levels. IGF-1 rose significantly on drug, as expected, and gait speed improved modestly — but most other functional measures showed no benefit. The trial's own conclusion states the finding that matters most here directly: "Trial was terminated early due to a safety signal of congestive heart failure in a limited number of patients," and closes with an unambiguous verdict: "MK-0677 has an unfavorable safety profile in this patient population⁷." That is a real, controlled trial stopped by its own investigators over a cardiac safety event — not a forum anecdote, not a theoretical mechanism concern, and not something either of sermorelin's own trials has an equivalent of.

The post-marketing picture, for both, with the same honest caveat

FDA's Adverse Event Reporting System (FAERS), counted live for this article, holds 12 reports naming ibutamoren — reaction terms include cerebrovascular accident, cold-type haemolytic anaemia, jaundice, liver injury, seizure, acute coronary syndrome, chest pain, and deep vein thrombosis⁸. That's a broader and more cardiovascular/hepatic-leaning spread than sermorelin's own 58 FAERS reports, which run mostly to local injection-site and hypersensitivity reactions⁹. The same caveat applies to both numbers, and it's worth repeating rather than letting the contrast speak for itself: these are tiny counts from a spontaneous, voluntary reporting system, not a controlled incidence rate, and they can't establish causation on their own. What they can do — and what the controlled trials above already established more directly — is corroborate that MK-677's reported safety concerns skew cardiometabolic, while sermorelin's skew local and dermatologic.

What this means for the actual decision

If you're weighing "which growth-hormone-axis option should I actually pursue," the honest layered answer is this. Neither MK-677 nor sermorelin is sold by a provider on this site's reviewed roster in a way that changes the underlying facts above — but our sermorelin provider rankings are this site's only board covering this category at all, because sermorelin is the compound this site's reviewed providers actually sell as a compounded product. MK-677 isn't a boarded product here, and given that its only marketed clinical-trial-scale safety data includes a trial stopped early for a cardiac signal, that gap shouldn't be read as an oversight. If tesamorelin or ipamorelin are the other options on your list, our sermorelin-vs-tesamorelin comparison and our ipamorelin-vs-sermorelin comparison cover those directly. Once you have an actual prescribed sermorelin dose, our reconstitution calculator does the vial-to-syringe arithmetic — there's no equivalent tool for MK-677 to link to, because there's nothing to reconstitute.

The bottom line

MK-677 is an oral, non-peptide small molecule, not a peptide, and its regulatory status is lower than sermorelin's: the only FDA-adjacent filing for it is an animal-drug bulk-ingredient listing, and FDA's own 503A list places it in the category reserved for significant safety concerns. Its best human evidence — a real 2-year RCT — found genuine fat-free mass gains alongside a measurable drop in insulin sensitivity, a rise in cortisol, and no functional benefit despite the added lean mass; a separate hip-fracture trial was stopped early over a congestive heart failure signal. Sermorelin's own evidence is thinner in adults, but its trial record carries no equivalent terminated-for-cardiac-safety finding. Those are two genuinely different risk profiles, not two flavors of the same compound.